INCB000928 + ruxolitinib

**INCB000928 + ruxolitinib** is a combination investigational therapy being evaluated primarily for anemia due to myeloproliferative disorders, most notably myelofibrosis. INCB000928 (zilurgisertib) is a selective, oral activin receptor-like kinase 2 (ALK2) inhibitor, designed to lower elevated hepcidin and improve anemia pathology[5][8][9]. Ruxolitinib is an oral inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) that targets aberrant JAK-STAT signaling central to myeloproliferative neoplasms[2][5]. This combination may offer mechanistic synergy: ALK2 inhibition reduces hepcidin-driven anemia, while JAK1/2 inhibition by ruxolitinib ameliorates the underlying disease process.

Other names

INCB000928 + ruxolitinibzilurgisertib + ruxolitinibINCB00928 + ruxolitinib